Association between Covishield vaccine and menstrual disturbance. Findings from a cross-sectional study among participants of Zero TB cohort in India

•Prevalence of any new menstrual disturbance after Covishield vaccine was 20%.•The cycles were mostly affected by less than 7 days, reversing within 1–3 cycles.•Previous SARS-CoV-2 infection was not associated with menstrual disturbance.•Emotional disturbance and previous dysmenorrhea are associated...

Full description

Saved in:

Bibliographic Details
Published in:	Vaccine Vol. 42; no. 16; pp. 3572 - 3577
Main Authors:	Dorjee, Kunchok, Namdon, Tenzin, Topgyal, Sonam, Gyatso, Ugen, Tsundue, Tenzin, Dolma, Tashi, Kumar, Vipan, Lhadon, Dekyi, Yangkyi, Tenzin, Khachoe, Tenzin, Dorjee, Sangyal, Sadoff, R.C., Peters, David, Gupta, Amita, Paster, Zorba, Chaisson, Richard E., Phunkyi, Dawa, Sadutshang, Tsetan D.
Format:	Journal Article
Language:	English
Published:	Netherlands Elsevier Ltd 11-06-2024 Elsevier Limited
Subjects:	Anxiety Bias Bleeding Cohort analysis Comorbidity COVID-19 COVID-19 diagnostic tests Covid-19 vaccine COVID-19 vaccines Disturbance Females Health surveillance Immunization Medical personnel Menstrual disturbance Menstruation Pandemics Population Post-menopause Regression analysis Severe acute respiratory syndrome coronavirus 2 Surveys Vaccines Women’s health India Menstrual disturbance Covid-19 vaccine Women’s health
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	•Prevalence of any new menstrual disturbance after Covishield vaccine was 20%.•The cycles were mostly affected by less than 7 days, reversing within 1–3 cycles.•Previous SARS-CoV-2 infection was not associated with menstrual disturbance.•Emotional disturbance and previous dysmenorrhea are associated with menstrual disturbance. The association between covid-19 vaccine and menstrual disturbance is unclear. An in-person cross-sectional survey among female members ≥ 18 years enrolled in an ongoing Zero TB prospective cohort in Northern India who had received one or two doses of covid-19 vaccine was conducted to study the characteristics and association of menstrual disturbance within six months of receiving Covishield. Between June 29 and September 5, 2021, 339 females ≥ 18 years of age were administered the survey. Median age was 30 (IQR: 22–39) years; 84 % were between 18 and 49 and 16 % were ≥ 50 years old. There were 152 college students, 27 healthcare workers, and 160 nuns. Forty-two women (12 %) had received one dose and 297 (88 %) had received two doses of Covishield. Overall, 66 (20 %) women reported experiencing menstrual disturbance after receiving Covishield vaccine. The problems included early menstruation: 6 % (n = 19/339); late menstruation: 4 % (n = 14/339); and heavier bleeding: 5 % (n = 17/339). Disturbances lasted for less than seven days and cycles normalized in 1–3 months. There was no post-menopausal bleeding. There was no significant difference in menstrual disturbance based on receiving one vs. two doses of Covishield (OR: 1.58; 95 % CI: 0.55–4.57; p = 0.381). History of SARS-CoV-2 infection was not associated with the development of menstrual disturbance among the vaccinees (OR: 0.63; 95 % CI: 0.24–1.73; p = 0.379). Presence of emotional disturbance at baseline (OR: 31; 95 % CI: 3.52–267; p = 0.002) or previous history of dysmenorrhea (OR: 41; 95 % CI: 8.7–196; p < 0.001) was associated with menstrual disturbance in the vaccinees, indicating their potential to confound or bias study results. Menstrual problems were reported by Covishield vaccinees, but they were minor and reversible within three months and do not constitute a ground for vaccine hesitancy. Studies designed to assess causal link taking care to avoid selection bias or confounding are needed.
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
ISSN:	0264-410X 1873-2518
DOI:	10.1016/j.vaccine.2024.04.063